[
    [
        {
            "time": "",
            "original_text": "华东医药乌司奴单抗生物类似药进入临床三期，剑指300亿元国内银屑病市场",
            "features": {
                "keywords": [
                    "华东医药",
                    "乌司奴单抗",
                    "生物类似药",
                    "临床三期",
                    "银屑病市场"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药乌司奴单抗生物类似药进入临床三期，剑指300亿元国内银屑病市场",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药银屑病单抗即将Ⅲ期临床，原研药乌司奴单抗垄断将破？",
            "features": {
                "keywords": [
                    "华东医药",
                    "银屑病单抗",
                    "Ⅲ期临床",
                    "乌司奴单抗",
                    "垄断"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药银屑病单抗即将Ⅲ期临床，原研药乌司奴单抗垄断将破？",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "冲击乌司奴单抗全球首仿，华东医药重磅新药进入三期临床",
            "features": {
                "keywords": [
                    "乌司奴单抗",
                    "全球首仿",
                    "华东医药",
                    "重磅新药",
                    "三期临床"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "冲击乌司奴单抗全球首仿，华东医药重磅新药进入三期临床",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-06",
            "original_text": "华东医药（000963.SZ）：将于6月启动HDM3001产品（QX001S）Ⅲ期临床试验",
            "features": {
                "keywords": [
                    "华东医药",
                    "HDM3001",
                    "QX001S",
                    "Ⅲ期临床试验",
                    "6月启动"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药（000963.SZ）：将于6月启动HDM3001产品（QX001S）Ⅲ期临床试验",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-06",
            "original_text": "华东医药（000963.SZ）：HDM3001产品（QX001S）将于6月开展Ⅲ期临床试验",
            "features": {
                "keywords": [
                    "华东医药",
                    "HDM3001",
                    "QX001S",
                    "Ⅲ期临床试验",
                    "6月"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药（000963.SZ）：HDM3001产品（QX001S）将于6月开展Ⅲ期临床试验",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药企资本运作加快：跨界、并购、股权转让",
            "features": {
                "keywords": [
                    "药企",
                    "资本运作",
                    "跨界",
                    "并购",
                    "股权转让"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药企资本运作加快：跨界、并购、股权转让",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "安信证券--商贸零售：4月社零同比增长19年同期8.8%，朗姿医美携手艾尔建美学开展国际战略合作【行业研究】",
            "features": {
                "keywords": [
                    "安信证券",
                    "商贸零售",
                    "社零增长",
                    "朗姿医美",
                    "艾尔建美学",
                    "战略合作"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "商贸零售",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安信证券--商贸零售：4月社零同比增长19年同期8.8%，朗姿医美携手艾尔建美学开展国际战略合作【行业研究】",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医美板块午前发力，华熙生物大涨9%",
            "features": {
                "keywords": [
                    "医美板块",
                    "华熙生物",
                    "大涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医美板块午前发力，华熙生物大涨9%",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药大涨",
            "features": {
                "keywords": [
                    "华东医药",
                    "大涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药大涨",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        }
    ]
]